147 related articles for article (PubMed ID: 36115384)
1. Excellent Long-term Clinical Response to Rivaroxaban in Livedoid Vasculopathy: A Retrospective Study.
Morgado-Carrasco D; Ibaceta J; Iranzo P; Bosch-Amate X; Mascaró-Galy JM
Actas Dermosifiliogr; 2023 Feb; 114(2):183-185. PubMed ID: 36115384
[No Abstract] [Full Text] [Related]
2. Livedoid vasculopathy in Koreans: clinical features and response to rivaroxaban treatment.
Lee JS; Cho S
J Eur Acad Dermatol Venereol; 2020 Apr; 34(4):e176-e178. PubMed ID: 31793049
[No Abstract] [Full Text] [Related]
3. Real-world data on pain management and effectiveness of anti-tumour necrosis factor agents in refractory livedoid vasculopathy.
Gao Y; Jin H
J Eur Acad Dermatol Venereol; 2022 Jan; 36(1):e46-e48. PubMed ID: 34416092
[No Abstract] [Full Text] [Related]
4. Prevention of livedoid vasculopathy recurrence by prolonged administration of rivaroxaban.
Drerup C; Goerge T
J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):e532. PubMed ID: 28609556
[No Abstract] [Full Text] [Related]
5. Treatment of Livedoid Vasculopathy With Rivaroxaban: A Potential Use of New Oral Anticoagulants for Dermatologists.
Jiménez-Gallo D; Villegas-Romero I; Rodríguez-Mateos ME; Linares-Barrios M
Actas Dermosifiliogr (Engl Ed); 2018 Apr; 109(3):278-281. PubMed ID: 29074145
[No Abstract] [Full Text] [Related]
6. Response of livedoid vasculopathy to rivaroxaban.
Winchester DS; Drage LA; Davis MD
Br J Dermatol; 2015 Apr; 172(4):1148-50. PubMed ID: 25255997
[No Abstract] [Full Text] [Related]
7. A novel combination ("CHAP") regimen for management of livedoid vasculopathy in 12 patients.
Coromilas AJ; Micheletti RG
J Am Acad Dermatol; 2023 Mar; 88(3):672-674. PubMed ID: 35787412
[No Abstract] [Full Text] [Related]
8. Evaluating complement dysregulation in livedoid vasculopathy using a functional assay.
Eswaran H; Chaturvedi S; Brodsky RA; Gerber GF; Pan XZ; Moll S
Blood Adv; 2023 Nov; 7(21):6604-6607. PubMed ID: 37722353
[No Abstract] [Full Text] [Related]
9. Exacerbation of livedoid vasculopathy after coronavirus disease 2019.
Kawabe R; Tonomura K; Kotobuki Y; Ueda-Hayakawa I; Murota H; Fujimoto M
Eur J Dermatol; 2022 Jan; 32(1):129-131. PubMed ID: 35653093
[No Abstract] [Full Text] [Related]
10. Characteristics, risk factors and treatment reality in livedoid vasculopathy - a multicentre analysis.
Weishaupt C; Strölin A; Kahle B; Kreuter A; Schneider SW; Gerss J; Eveslage M; Drabik A; Goerge T
J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):1784-1791. PubMed ID: 31009111
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Livedoid Vasculopathy With Baricitinib.
Song X; Tu P
JAMA Dermatol; 2022 May; 158(5):587-589. PubMed ID: 35353137
[No Abstract] [Full Text] [Related]
12. Efficacy of adalimumab in the treatment of refractory livedoid vasculopathy: Case report and literature review.
Dong L; Li Q; Yu Y; Liang J; Zhang X
Dermatol Ther; 2022 Sep; 35(9):e15666. PubMed ID: 35760761
[No Abstract] [Full Text] [Related]
13. The potential role of tumor necrosis factor-α in thrombosis in livedoid vasculopathy.
Qi F; Jin H
Arch Dermatol Res; 2024 Apr; 316(5):124. PubMed ID: 38637417
[No Abstract] [Full Text] [Related]
14. Rivaroxaban prevents painful cutaneous infarctions in livedoid vasculopathy.
Kerk N; Drabik A; Luger TA; Schneider SW; Goerge T
Br J Dermatol; 2013 Apr; 168(4):898-9. PubMed ID: 23106384
[No Abstract] [Full Text] [Related]
15. Refractory livedoid vasculopathy in a child successfully treated with baricitinib.
Zhang H; Chen J; Wu N; Chen H; Liu Y
Dermatol Ther; 2022 Aug; 35(8):e15659. PubMed ID: 35726859
[No Abstract] [Full Text] [Related]
16. Intravenous immunoglobulin in resistant livedoid vasculopathy: Analysis of a case series.
Ozden MG; Ozdemir H; Şenturk N
Dermatol Ther; 2020 Mar; 33(2):e13229. PubMed ID: 31965687
[TBL] [Abstract][Full Text] [Related]
17. The management of livedoid vasculopathy focused on direct oral anticoagulants (DOACs): four case reports successfully treated with rivaroxaban.
Franco Marques G; Criado PR; Alves Batista Morita TC; Cajas García MS
Int J Dermatol; 2018 Jun; 57(6):732-741. PubMed ID: 29663354
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of intravenous immunoglobulins in livedoid vasculopathy: long-term follow-up of 11 patients.
Monshi B; Posch C; Vujic I; Sesti A; Sobotka S; Rappersberger K
J Am Acad Dermatol; 2014 Oct; 71(4):738-44. PubMed ID: 25022849
[TBL] [Abstract][Full Text] [Related]
19. Dabigatran in the management of livedoid vasculopathy.
Sawada T; Suehiro M
Clin Exp Dermatol; 2017 Mar; 42(2):237-239. PubMed ID: 28052437
[No Abstract] [Full Text] [Related]
20. Livedoid vasculopathy in a patient with lupus anticoagulant and MTHFR mutation: treatment with low-molecular-weight heparin.
Abou Rahal J; Ishak RS; Otrock ZK; Kibbi AG; Taher AT
J Thromb Thrombolysis; 2012 Nov; 34(4):541-4. PubMed ID: 22592843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
